Hints and tips:
...A lot has happened in the past few days....
...US, Federal Open Market Committee makes interest rate announcement with officials signalling a 75 basis point rise Results: Airbus H1, BASF Q2, Boeing Q2, Breedon H1, Bristol Myers Squibb Q2, British...
...All assets may perform badly under stagflation, but we’d rather own Pepsi, Johnson & Johnson, Kimberly-Clark, Bristol-Myers et al than sit and watch our cash lose its earnings power....
...Pharmaceutical company earnings Drugmaker Bristol-Myers Squibb is scheduled to report fourth-quarter results and is expected to post a higher profit than last year on increased sales of its cancer drugs...
...From the pharmaceuticals sector, Bristol-Myers Squibb — which recently agreed to buy Celgene in one of the largest pharmaceutical deals in history — reports....
...According to SEC filings, Elon Musk’s company is the $60bn hedge fund’s second largest holding, behind Bristol-Myers Squibb....
...The sale allows Bristol-Myers Squibb to push ahead with its mammoth $90bn takeover of Celgene....
...The two banks have landed on some of the biggest deals of the year, with JPMorgan advising on the $90bn tie-up between Bristol-Myers Squibb and Celgene and Goldman providing advice to Allergan on its $85bn...
...Bristol-Myers Squibb, a mammoth US drugmaker on the brink of completing a $90bn merger with Celgene — one of the largest in pharma history — is Starboard’s latest target....
...Bristol Myers Squibb was a rare gainer, its shares lifting 1.7 per cent to $21.02 after the US Food and Drug Administration said analyses of its experimental diabetes drug showed it met the agency’s guidelines...
International Edition